Welcome to our dedicated page for Y-mAbs Therapeutics news (Ticker: YMAB), a resource for investors and traders seeking the latest updates and insights on Y-mAbs Therapeutics stock.
Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) is a commercial-stage biopharmaceutical company dedicated to the development and commercialization of novel, antibody-based therapeutic products for cancer treatment. The company focuses on addressing unmet medical needs, particularly in pediatric oncology, and aims to become a leader in this field.
The company's advanced product pipeline includes two pivotal-stage product candidates: naxitamab and omburtamab. Naxitamab targets tumors expressing GD2, while omburtamab targets those expressing B7-H3. Y-mAbs' flagship FDA-approved product, DANYELZA® (naxitamab-gqgk), is a recombinant humanized immunoglobulin G subtype 1k monoclonal antibody designed to treat relapsed or refractory high-risk neuroblastoma in bone or bone marrow.
Y-mAbs is also pioneering novel technologies such as the investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy (PRIT) platform and bispecific antibodies generated via the Y-BiClone platform. These innovative approaches aim to deliver optimal cancer therapy with minimal toxicity, leveraging existing infrastructure and enhancing patient care.
Financially, Y-mAbs has shown robust performance with increasing revenues from DANYELZA. For the fourth quarter of 2023, the company reported DANYELZA net product revenues of $23.4 million, up 42% year-over-year. The annual revenue reached $84.3 million, marking a 71% increase over the previous year. As of December 31, 2023, the company has delivered DANYELZA to 58 centers across the U.S.
In the first quarter of 2024, Y-mAbs continued its upward trajectory with U.S. DANYELZA net product revenues amounting to $18.6 million. The company maintains a strong financial foundation with approximately $75.7 million in cash and cash equivalents as of March 31, 2024, expected to support operations into 2027.
Y-mAbs collaborates with renowned institutions like Memorial Sloan Kettering Cancer Center (MSK), with exclusive licenses for technologies developed by MSK researchers. This ongoing partnership enhances Y-mAbs' capabilities in advancing their innovative therapeutic platforms.
The company's mission is clear: to transform cancer treatment outcomes by providing better and safer therapies for both children and adults. With continued advancements and strategic partnerships, Y-mAbs remains at the forefront of biopharmaceutical innovation.
Y-mAbs Therapeutics (NASDAQ: YMAB) presented preclinical data and trial progress for its CD38-SADA platform at the 2024 ASH Annual Meeting. The preclinical data demonstrated selective binding and anti-tumor efficacy of CD38-SADA when used with Lutetium 177-DOTA in treating Non-Hodgkin Lymphoma (NHL).
The company also presented details of its ongoing Phase 1 Trial 1201, evaluating CD38-SADA PRIT with Lu177-DOTA in adults with relapsed or refractory NHL. The trial consists of two parts: Part A focuses on dose escalation of CD38-SADA protein, while Part B aims to establish the optimal therapeutic dose of Lu177-DOTA. Both parts follow a 3+3 trial design with 4 planned dose levels.
Y-mAbs Therapeutics (Nasdaq: YMAB), a commercial-stage biopharmaceutical company specializing in radioimmunotherapy and antibody-based cancer treatments, has announced its participation in Citi's 2024 Global Healthcare Conference. The company's management team will conduct one-on-one meetings at the conference on December 4, 2024 in Miami, FL. Interested parties can schedule meetings through their Citi representative or by contacting cdu@ymabs.com.
Y-mAbs Therapeutics reported Q3 2024 financial results with total DANYELZA net product revenues of $18.5 million, marking a 10% decline from Q3 2023. The company entered into an exclusive license agreement with Nobelpharma for DANYELZA in Japan, securing a $2.0 million upfront payment. Key developments include the extension of DANYELZA's U.S. patent through February 2034 and market expansion into Turkey. Net loss for Q3 2024 was $7.0 million ($0.16 per share), compared to $7.7 million in Q3 2023. The company maintains its 2024 guidance with expected total net revenues between $87-95 million and cash position supporting operations into 2027.
Y-mAbs Therapeutics (NASDAQ: YMAB) and Nobelpharma have signed an exclusive license and distribution agreement for DANYELZA® in Japan. The agreement covers the development and commercialization of DANYELZA for treating relapsed/refractory high-risk neuroblastoma and potentially relapsed osteosarcoma. Y-mAbs will receive a $2.0 million upfront payment and could earn up to $31.0 million in milestone payments, plus profit sharing on commercial sales. Nobelpharma will handle regulatory submissions, marketing, sales, and distribution in Japan.
Y-mAbs Therapeutics (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on radioimmunotherapy and antibody-based cancer treatments, has scheduled its third quarter 2024 financial results announcement. The company will release results before market open on November 8, 2024, followed by a conference call and webcast at 8:00 a.m. ET. Domestic investors can dial (877) 407-0792, while international investors can use (201) 689-8263 to participate.
Y-mAbs Therapeutics (Nasdaq: YMAB), a commercial-stage biopharmaceutical company specializing in novel radioimmunotherapy and antibody-based therapeutic products for cancer treatment, has announced its participation in two upcoming investor conferences in October 2024:
1. Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit:
- Date: Tuesday, October 8, 2024
- Time: 9:30 a.m. ET
- Location: New York, NY
- Panel: "The Next Wave of TRTs – Targets, Targeting Technologies and Isotopes"
2. BMO Oncology Summit:
- Date: Tuesday, October 8, 2024
- Time: 3:00 p.m. ET
- Location: New York, NY
- Fireside chat: "Shifting the Antibody Paradigm"
These conferences provide Y-mAbs with opportunities to showcase its developments in cancer therapeutics and engage with investors.
Y-mAbs Therapeutics (Nasdaq: YMAB) presented new clinical and preclinical data on naxitamab and GD2-SADA for neuroblastoma treatment at the AACR Special Conference. Key findings include:
1. Naxitamab with GM-CSF achieved a 63% disease control rate in refractory/relapsed high-risk neuroblastoma patients.
2. GD2-SADA demonstrated high-affinity binding to Tb-DOTA, supporting its potential in pre-targeted radiotherapy (PRIT).
3. Ongoing clinical trials: Trial 201 for naxitamab, Trial 1001 for GD2-SADA PRIT in adolescents and adults, and planned Trial 1002 for pediatric patients.
These results highlight Y-mAbs' progress in developing innovative treatments for high-risk neuroblastoma, the most common extracranial solid tumor in children.
Y-mAbs Therapeutics (Nasdaq: YMAB), a commercial-stage biopharmaceutical company specializing in novel radioimmunotherapy and antibody-based therapeutic products for cancer treatment, has announced its participation in two upcoming investor conferences. Michael Rossi, President and CEO, will represent the company at:
1. Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024, at 1:50 p.m. ET in New York, NY.
2. Cantor Global Healthcare Conference on September 17, 2024, at 3:40 p.m. ET in New York, NY.
Both events will feature fireside chats and investor 1x1 meetings. Live webcasts of the fireside chats and related materials will be available on Y-mAbs' investor relations website under the Presentations section, with archives accessible for at least 30 days.
Y-mAbs Therapeutics (YMAB) reported Q2 2024 financial results and corporate developments. Highlights include:
- DANYELZA net product revenues of $22.8 million, up 10% YoY
- Geographic expansion with new revenues from Brazil and Mexico
- Phase 1 GD2-SADA Trial Part A expected completion in Q4 2024
- Appointed new CFO and Chief Development Officer
- Cash and cash equivalents of $77.8 million as of June 30, 2024
- Updated Full Year 2024 Total Net Revenue guidance
The company reported a net loss of $9.2 million ($0.21 per share) for Q2 2024, compared to a $6.3 million loss ($0.14 per share) in Q2 2023. Management expects current cash to support operations into 2027.
Y-mAbs Therapeutics (Nasdaq: YMAB), a commercial-stage biopharmaceutical company specializing in novel radioimmunotherapy and antibody-based cancer treatments, has announced its participation in two upcoming investor conferences in August 2024:
1. Wedbush PacGrow Healthcare Conference on August 13 in New York, NY, featuring investor 1x1 meetings.
2. Canaccord Genuity 44th Annual Growth Conference on August 14 in Boston, MA, including a fireside chat at 8:00 a.m. ET and investor 1x1 meetings.
A live webcast of Y-mAbs' fireside chat and related materials will be available on the company's investor relations website. The webcast will be archived for at least 30 days.
FAQ
What is the current stock price of Y-mAbs Therapeutics (YMAB)?
What is the market cap of Y-mAbs Therapeutics (YMAB)?
What is Y-mAbs Therapeutics, Inc.?
What products does Y-mAbs offer?
What are Y-mAbs' key technologies?
What recent financial results has Y-mAbs reported?
How many centers are using DANYELZA?
What is Y-mAbs' mission?
Who are Y-mAbs' notable collaborators?
What is the SADA PRIT platform?
How is Y-mAbs financially positioned?
What future developments are expected from Y-mAbs?
